Diagnostic means useful for predictive assessment of human hepatocellular carcinoma disease (HCC), as well as diagnostic methods using the same

• US 6,410,724 B1
• Filed: 01/21/2000
• Issued: 06/25/2002
• Est. Priority Date: 04/07/1997
• Status: Expired due to Fees

• Current Assignee: Institut National De La Sante Et De La Recherche Medicale (Inserm) (Allianz Global Investors GmbH), Institut Pasteur
• Original Assignee: Institut National De La Sante Et De La Recherche Medicale (Inserm) (Allianz Global Investors GmbH), Institut Pasteur
• Inventors: Buendia, Marie-Annick, Pineau, Pascal, Nagai, Hisaki, Dejean, Anne, Tiollais, Pierre
• Primary Examiner(s): Jones, W. Gary
• Assistant Examiner(s): GOLDBERG, JEANINE ANNE
• Application Number:
  US09/402,453
• Time in Patent Office: 886 Days
• Field of Search: 536/23.1, 536/24.3, 536/24.33, 536/24.31, 435/6
• US Class Current: 536/24.3
• CPC Class Codes: C12Q 1/6886 for cancer immunoassay for cancer G01N33/574
• CPC Class Codes: C12Q 2600/156 Polymorphic or mutational markers

Abstract

The present invention pertains to new polynucleotides or new combinations of polynucleotides useful as diagnostic tools for predicting the occurrence of a human hepatocellular carcinoma disease. The invention is also directed to polynucleotides that consist in candidate tumor suppressor genes the alteration of which is involved in the occurrence of hepatocellular carcinoma in a patient, as well as to polynucleotides derived from such new candidate tumor suppressor genes and to the corresponding expressed polypeptides. The invention also concerns diagnostic methods using said polynucleotides as diagnostic tools.

Claims

1. A composition for the predictive diagnosis of an hepatocellular carcinoma in a patient consisting essentially of a first isolated polynucleotide primer or a pair of isolated polynucleotide primers capable of specifically detecting or amplifying a first microsatellite DNA marker and a second isolated polynucleotide primer or a pair of isolated polynucleotide primers capable of specifically detecting or amplifying a second microsatellite DNA marker, wherein:

said first microsatellite DNA marker is selected from the group consisting of D1S235, D1S238, D2S125, D2S336, D7S495, D8S263, D9S164, D9S273, and D17S928; and

in that;

said second microsatellite DNA marker is selected from the group consisting of D1S199, D1S235, D1S238, D1S247, D1S255, D1S436, D1S478, D1S2644, D1S2828, D2S125, D2S336, D4S400, D4S426, D4S1564, D4S1572, D4S1616, D4S2937, D4S2945, D6S305, D7S493, D7S495, D8S262, D8S263, D8S264, D8S277, D8S518, D8S1469, D8S1721, D8S1731, D8S1742, D8S1752, D8S1819, D9S164, D9S273, D13S284, D14S81, D14S265, D14S280, D14S292, D14S995, D16S402, D16S422, D16S505, D16S511, D16S3098, D17S786 and D17S928; and

providing that said first and said second microsatellite DNA markers are not the same.

2. A composition according to claim 1, wherein said first microsatellite DNA marker is selected from the group consisting of D1S238, D1S235, D2S336, D2S125, D7S495, D9S164 and D17S928.

3. A composition according to claim 1, wherein said second microsatellite DNA marker is selected from the group consisting of D4S426, D6S305, D7S493, D8S277, D13S284 and D17S786.

4. A composition according to claim 1, wherein said second microsatellite DNA marker is selected from the group consisting of D8S1742, D8S1469, D8S1731, D8S1752, D1S2644, D1S199, D1S478, D1S2828, D1S247, D1S255, D14S280, D14S995, D14S81, D14S265, D14S292, D16S3098, D16S505, D16S511, D16S422 and D16S402.

5. A composition for the predictive diagnosis of an hepatocellular carcinoma in a patient wherein said composition comprises:

a) an isolated polynucleotide primer or a pair of isolated polynucleotide primers capable of specifically detecting or amplifying the D14S81 microsatellite DNA marker;

b) an isolated polynucleotide primer or a pair of isolated polynucleotide primers capable of specifically detecting or amplifying a microsatellite DNA marker selected from the group consisting of D8S264, D8S262, D8S518, D8S1742, D8S277, D8S1819, D8S1721, D8S1731 and D8S1752;

c) an isolated polynucleotide primer or a pair of isolated polynucleotide primers capable of specifically detecting or amplifying a microsatellite DNA marker selected from the group consisting of D1S436, D1S2644, D1S199, D1S478, D1S2828, D1S247 and D1S255;

d) an isolated polynucleotide primer or a pair of isolated polynucleotide primers capable of specifically detecting or amplifying a microsatellite DNA marker selected from the group consisting of D16S3098, D16S505, D16S511, D16S422 and D16S402; and

e) an isolated polynucleotide primer or a pair of isolated polynucleotide primers capable of specifically detecting or amplifying a microsatellite DNA marker selected from the group consisting of D4S400, D4S1572, D4S1564, D4S2945, D4S1616 and D4S2937.